General and administrative expenses increased to $35.2 million from $27.6 million, driven by higher professional services fees and personnel-related costs including stock-based compensation.
Gross margin remained consistent at 93%, with cost of goods sold at $7.2 million compared to $6 million in the prior year quarter.
Krystal Biotech reported Q2 2025 net VYJUVEK revenue of $96 million, marking continued growth compared to Q2 2024 and a 9% increase over Q1 2025.
Net income was $38.3 million or $1.33 per basic share and $1.29 per diluted share, compared to $15.6 million or $0.54 per basic share in the prior year quarter.
Operating expenses included $14.1 million in noncash stock-based compensation, up from $13.2 million in Q2 2024.
R&D expenses decreased to $14.4 million from $15.6 million year-over-year, primarily due to timing of manufacturing runs, offset by increased clinical development costs.
The company ended the quarter with over $820 million in combined cash and investments, supporting upcoming launches and R&D objectives.
Total net VYJUVEK revenue since launch exceeded $525 million.
Dafinchi